Abstract
Pharmacologic therapy represents the mainstay of treatment for heart failure in children. However, medical therapy for this population is not widely standardized. This is mainly due to the heterogeneity of potential etiologies, the specific challenge of patients with univentricular physiology and the lack of evidence-based prospective randomized clinical trials in pediatric patients. In fact, most current strategies are based largely on extrapolated data from adult studies. Although the classic drugs for heart failure i.e. diuretics, angiotensin-converting enzyme inhibitors, β-blockers and cardiac glycosides, still play a major role in the treatment of pediatric heart failure, newer alternative therapies such as levosimendan and nesiritide are increasingly utilized with promising early results. A systematic literature search of PubMed and MEDLINE databases using relevant terms was performed. All clinical trials and relevant manuscripts about the current pharmacologic treatment of heart failure in the pediatric population were reviewed. New drugs such as levosimendan and nesiritide and the treatment of single-ventricle patients were also included.
Keywords: Pediatric heart failure, diuretics, angiotensin-converting enzyme inhibitor, β-blocker, nesiritide, levosimendan, arrhythmia, anemia, digitalis, aldosterone
Current Vascular Pharmacology
Title: Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Volume: 9 Issue: 5
Author(s): Victor Bautista-Hernandez, Antonio Sanchez-Andres, Francisco Portela and Francis Fynn-Thompson
Affiliation:
Keywords: Pediatric heart failure, diuretics, angiotensin-converting enzyme inhibitor, β-blocker, nesiritide, levosimendan, arrhythmia, anemia, digitalis, aldosterone
Abstract: Pharmacologic therapy represents the mainstay of treatment for heart failure in children. However, medical therapy for this population is not widely standardized. This is mainly due to the heterogeneity of potential etiologies, the specific challenge of patients with univentricular physiology and the lack of evidence-based prospective randomized clinical trials in pediatric patients. In fact, most current strategies are based largely on extrapolated data from adult studies. Although the classic drugs for heart failure i.e. diuretics, angiotensin-converting enzyme inhibitors, β-blockers and cardiac glycosides, still play a major role in the treatment of pediatric heart failure, newer alternative therapies such as levosimendan and nesiritide are increasingly utilized with promising early results. A systematic literature search of PubMed and MEDLINE databases using relevant terms was performed. All clinical trials and relevant manuscripts about the current pharmacologic treatment of heart failure in the pediatric population were reviewed. New drugs such as levosimendan and nesiritide and the treatment of single-ventricle patients were also included.
Export Options
About this article
Cite this article as:
Bautista-Hernandez Victor, Sanchez-Andres Antonio, Portela Francisco and Fynn-Thompson Francis, Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642733
DOI https://dx.doi.org/10.2174/157016111796642733 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Current Pharmaceutical Design Synergistic Two-Way Interactions of Dietary Polyphenols and Dietary Components on the Gut Microbial Composition: Is There a Positive, Negative, or Neutralizing Effect in the Prevention and Management of Metabolic Diseases?
Current Protein & Peptide Science Editorial [Hot Topic Intracellular Calcium Signaling: Holding the Balance between Health and Disease Guest Editor: Luca Munaron]
Current Medicinal Chemistry The Role of Angiogenesis in Coronary Artery Disease: A Double-Edged Sword: Intraplaque Angiogenesis in Physiopathology and Therapeutic Angiogenesis for Treatment
Current Pharmaceutical Design Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Effect of Frozen Storage on Quality Changes of Five Fish Species from South Caspian Sea
Current Nutrition & Food Science Non-Pharmacologic Treatment Options in Rheumatologic Disease
Current Rheumatology Reviews Prophylaxis of Cancer
Current Cancer Therapy Reviews Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Walnut Extract Inhibits the Fibrillization of Amyloid Beta-Protein, and also Defibrillizes its Preformed Fibrils
Current Alzheimer Research Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Editorial: Inflammation and Heart Diseases
Current Pharmaceutical Design Application of Stem Cells in Cardiology: Where we are and where we are Going
Current Stem Cell Research & Therapy Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Use of Cardiac Biomarkers in Various Heart Conditions
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry Analysis of Current Antifungal Agents and Their Targets within the Pneumocystis carinii Genome
Current Drug Targets Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Opioid-induced Cardioprotection
Current Pharmaceutical Design